The National Hemophilia Foundation (NHF) and Medscape are pleased to announce the first live activity in a Virtual Grand Round Series on “Gene Therapy for Patients with Hemophilia.”
The program, presented through a collaboration between the NHF and Medscape, was designed to foster expert discussion on new insights based on the latest data from phase 3 gene therapy trials. The opening activity, which will be held on Tuesday, October 10, 2022, from 12pm-1pm ET, is intended for hematologists, nurses/nurse practitioners, pediatricians, primary care physicians, and physician assistants.
Participants who complete the activity will:
Have increased knowledge regarding the
Clinical trial data on gene therapy for hemophilia
Implications of gene therapy in the management of hemophilia
Demonstrate greater confidence in their ability to
Implement gene therapy in an interprofessional care team environment
There is no cost associated with this activity. Visit the event homepage for more information, including accreditation details, and to register.
This program is supported by independent educational grant from CSL Behring and Spark Therapeutics.